💊 Australians living with multiple sclerosis, rare cancers and other serious conditions will benefit from new and expanded listings on the PBS, giving access to life-changing medicines. These listings include Ocrelizumab (MS treatment), new cancer immunotherapy Toripalimab (recurrent or metastatic nasopharyngeal carcinoma), and expanded access to Bimekizumab (skin condition hidradenitis suppurativa) and Pegcetacoplan (blood disorder paroxysmal nocturnal haemoglobinuria). Eligible patients will pay a maximum of $31.60 per script, or just $7.70 with a concession card, dropping to just $25 per script from 1 January 2026. Since July 2022, the Albanese Government has approved extra funding for 386 new and amended PBS listings. 💉💊 #auspol #pbsmedicine #cheapermedicines #health #multiplesclerosis #immunotherapy @Mark_Butler_MP @AustralianLabor